Abstract
Cancer immunotherapy with interleukin-2 (IL-2) has demonstrated long term disease control in metastatic renal cell carcinoma and malignant melanoma. With introduction of novel kinase inhibitors, immunomodulatory molecules, cytokines, and vaccines for treatment of cancer there is an increased interest in combining these therapeutic strategies with IL-2. Here we discuss toxicity and established activity of IL-2 in the management of advanced malignancies, and speculate on future use of this cytokine for treatment of cancer.
Keywords: Interleukin-2, kidney cancer, melanoma, immunotherapy, Cancer Therapy, (IL-2), cell carcinoma, malignant melanoma, (IL-2R), phosphorylation, tyrosine kinase, TNF alpha and beta, T-cells, transient fever, lymphopenia, Metastatic Melanoma, Renal Cell Cancer, renal cell carcinoma, IL-2 therapy, HIGH DOSE IL-2, fever, chills, lethargy, diarrhea, nausea, anemia, thrombocytopenia, eosinophilia, hepatic enzymes elevation, erythroderma, confusion, eosinophilic myocarditis, cardiac stress test, (Eastern Coopera-tive Oncology Group Scale, Interferon, tumor infiltrating lymphocytes (TILs), Phase III clinical trial, Phase II clinical trial, biochemotherapy (BCT), Interferon-alpha, inhibitors, metastatic kidney cancer, malig-nant melanoma
Current Medicinal Chemistry
Title: Interleukin 2 in Cancer Therapy
Volume: 17 Issue: 29
Author(s): G. K. Antony and A. Z. Dudek
Affiliation:
Keywords: Interleukin-2, kidney cancer, melanoma, immunotherapy, Cancer Therapy, (IL-2), cell carcinoma, malignant melanoma, (IL-2R), phosphorylation, tyrosine kinase, TNF alpha and beta, T-cells, transient fever, lymphopenia, Metastatic Melanoma, Renal Cell Cancer, renal cell carcinoma, IL-2 therapy, HIGH DOSE IL-2, fever, chills, lethargy, diarrhea, nausea, anemia, thrombocytopenia, eosinophilia, hepatic enzymes elevation, erythroderma, confusion, eosinophilic myocarditis, cardiac stress test, (Eastern Coopera-tive Oncology Group Scale, Interferon, tumor infiltrating lymphocytes (TILs), Phase III clinical trial, Phase II clinical trial, biochemotherapy (BCT), Interferon-alpha, inhibitors, metastatic kidney cancer, malig-nant melanoma
Abstract: Cancer immunotherapy with interleukin-2 (IL-2) has demonstrated long term disease control in metastatic renal cell carcinoma and malignant melanoma. With introduction of novel kinase inhibitors, immunomodulatory molecules, cytokines, and vaccines for treatment of cancer there is an increased interest in combining these therapeutic strategies with IL-2. Here we discuss toxicity and established activity of IL-2 in the management of advanced malignancies, and speculate on future use of this cytokine for treatment of cancer.
Export Options
About this article
Cite this article as:
K. Antony G. and Z. Dudek A., Interleukin 2 in Cancer Therapy, Current Medicinal Chemistry 2010; 17 (29) . https://dx.doi.org/10.2174/092986710793176410
DOI https://dx.doi.org/10.2174/092986710793176410 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cetuximab: Its Use in Combination with Radiation Therapy and Chemotherapy in the Multimodality Treatment of Head and Neck Cancer
Recent Patents on Anti-Cancer Drug Discovery Na+-H+ Exchanger, pH Regulation and Cancer
Recent Patents on Anti-Cancer Drug Discovery Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) Optimizing Tumor-Reactive γδT Cells for Antibody-Based Cancer Immunotherapy
Current Molecular Medicine Enzymes Metabolizing Aristolochic Acid and their Contribution to the Development of Aristolochic Acid Nephropathy and Urothelial Cancer
Current Drug Metabolism Pharmacological Intervention at CCR1 and CCR5 as an Approach for Cancer: Help or Hindrance
Current Topics in Medicinal Chemistry O-(2-[18F]-Fluoroethyl)-L-Tyrosine (FET) in Neurooncology: A Review of Experimental Results
Current Radiopharmaceuticals Nanoparticle Albumin - Bound (NAB) Technology is a Promising Method for Anti-Cancer Drug Delivery
Recent Patents on Anti-Cancer Drug Discovery CD40L - A Multipotent Molecule for Tumor Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Ellipticine, its Derivatives: Re-evaluation of Clinical Suitability with the Aid of Drug Delivery Systems
Current Cancer Drug Targets Iron Oxide Nanoparticles: An Insight into their Biomedical Applications
Current Medicinal Chemistry Phytosterols in Cancer: From Molecular Mechanisms to Preventive and Therapeutic Potentials
Current Medicinal Chemistry A Single Center Phase II Study of Continuous Infusion of Low-dose 5- fluorouracil for Heavily Pretreated Patients With Metastatic Colorectal Cancer
Clinical Cancer Drugs MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance
Current Drug Targets Anticancer Antifolates: Current Status and Future Directions
Current Pharmaceutical Design Cytoprotection and Immunomodulation in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment
Current Vascular Pharmacology Pharmaco-Therapeutic Challenges in Cancer Biology with Focus on the Immune- System Related Risk Factors
Current Pharmaceutical Design Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)
Recent Patents on Anti-Cancer Drug Discovery The Roles of Parathyroid Hormone and Calcitonin in Bone Remodeling: Prospects for Novel Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets